Results 61 to 70 of about 1,349 (113)

Bruton's Agammaglobulinemia: Case Series and Literature Review From King Fahad Central Hospital, Jizan, Saudi Arabia. [PDF]

Am J Case Rep
Shamakhi A, Dhayhi N, Matabi S, Maashi M, Hamdi AD, Ali B, Hazazi F, Alhamoud AH.   +7 more
europepmc   +1 more source

Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [PDF]

Eur J Haematol
Tidswell R, Owen C, Shafey M, Perry S, Cox-Kennett N, Sterrett R, Peters A, Puckrin R.   +7 more
europepmc   +1 more source

NLRP3 inflammasome-mediated platelet hyperreactivity in sickle cell mice is targetable by BTK inhibition. [PDF]

Biochem Biophys Res Commun
Vogel S, Kamimura S, Nguyen E, Smith M, Almeida LEF, Zerfas P, Bharti K, Combs C, de Melo MS, Quezado ZMN.   +9 more
europepmc   +1 more source

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. [PDF]

Cancer
Coste A, Sritharan N, Lok A, Tomowiak C, Ferrant E, Clavert A, Roos-Weil D, Bouclet F, Caillet A, Croizier C, Stocker N, Tchernonog E, Feugier P, Santagostino A, Hivert B, Michallet AS, De Guibert S, Lara D, Waultier-Rascalou A, Merabet F, Durand A, Bussot L, Laribi K, Dilhuydy MS, Lévy V, Quinquenel A.   +25 more
europepmc   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study. [PDF]

J Neurooncol
Chang X, He Z, Wang H, Zhu H, Guo Y, Zou D, Zhao Z, Song T, Hu R, Ni J, Zhao H, Hui W, Liu Z, Li Z, Zhang W, Zhou D, Zhang Y, Sun W.   +17 more
europepmc   +1 more source

Fatal X-linked agammaglobulinemia complicated by septic shock: a case report and comprehensive review of novel BTK mutations. [PDF]

Front Immunol
Wu P, You W, Liu W, Luo N, Xu J.
europepmc   +1 more source

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. [PDF]

ChemMedChem
Almodóvar-Rivera CM, Tandon I, Mudududdla R, Esguerra PN, Lucio-Acero K, Tang W.   +5 more
europepmc   +1 more source

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +1 more source

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy. [PDF]

Blood Cancer J
Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Danilov A, Argao C, Ruan J, Nizamuddin IA, Kahl BS, Grover NS, Khan NB, Pongas GN, Lossos IS, Ouchveridze E, Tun AM, Baidoun F, Alhaj Moustafa M, Harris ZI, Munoz JL, Young PR, Portell CA, Reagan PM, Ryan CE, Merryman RW, Velayati A, Greenwell IB, Gerber DG, Jain P, Wang ML, Ayyappan SR, Mou E, Banaszak LG, Pophali PA, Stack AC, Messmer MR, Narkhede MS, Mehta A, Moyo TK, Ghosh N, Bhansali RS, Barta SK, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P.   +55 more
europepmc   +1 more source